Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Combinations for LSTR in Primary Molars
NCT06818578Phase 4Completed
- Sponsor
- Inonu University
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clindamycin in pulp necrosis and irreversible pulpitis (2 arms), sponsored by Inonu University. Primary endpoints: Clinical Success at 12 months, Radiographic Success at 12 months and 1 more. Started Sep 2022; status: completed.
02
Drugs
clindamycin
03
Conditions
pulp necrosisirreversible pulpitis
Beyond the preview
Go deeper on NCT06818578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818578.